Hikma returns after spring

Branded and generic medicines company Hikma Pharmaceuticals has returned to growth in some of its key Middle Eastern and North Africa (MENA) markets after the disruption caused by the Arab Spring. The improvement meant like-for-like group sales grew by 7.6 per cent and helped maintain adjusted operating profits at $146m (£93m).

To continue reading, register today

to enjoy limited access to the following:

  • Daily trading news
  • Funds coverage
  • Features on big investment themes
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now